Alpha 2.0
Login Register
» Authors » Dominique Hetuin

Dominique Hetuin

Explore the profile of Dominique Hetuin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 491
Followers 0
Related Specialties
Pharmacology
Oncology
Molecular Biology
Top 10 Co-Authors
Bruno Quesnel
Aurore Saudemont
Jizhong Liu
Nathalie Jouy
Abdelbasset Hamrouni
Kazimierz Kuliczkowski
Jerome Fagart
Celine Berthon
Michel Fay
Thomas Wickham
Published In
Blood
Cancer Immunol Immunother
Mol Ther
Mol Pharmacol
Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
A structural explanation of the effects of dissociated glucocorticoids on glucocorticoid receptor transactivation
Dezitter X, Fagart J, Taront S, Fay M, Masselot B, Hetuin D, et al.
Mol Pharmacol . 2013 Nov; 85(2):226-36. PMID: 24225022
There is a therapeutic need for glucocorticoid receptor (GR) ligands that distinguish between the transrepression and transactivation activity of the GR, the later thought to be responsible for side effects....
2.
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors
Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N, et al.
Cancer Immunol Immunother . 2010 Sep; 59(12):1839-49. PMID: 20814675
B7-H1 (PD-L1) is a B7-related protein that inhibits T-cell responses. B7-H1 participates in the immunoescape of cancer cells and is also involved in the long-term persistence of leukemic cells in...
3.
Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1
Saudemont A, Hamrouni A, Marchetti P, Liu J, Jouy N, Hetuin D, et al.
Cancer Res . 2007 May; 67(9):4491-8. PMID: 17483365
In the BCR/ABL DA1-3b mouse model of acute myelogenous leukemia, dormant tumor cells may persist in the host in a state of equilibrium with the CD8(+) CTL-mediated immune response by...
4.
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al.
Blood . 2007 Mar; 110(1):296-304. PMID: 17363736
Multiple myeloma (MM) cells inhibit certain T-cell functions. We examined the expression of B7-H1 (PD-L1), a B7-related protein that inhibits T-cell responses, in CD138-purified plasma cells isolated from MM patients,...
5.
Induction of leukemia-specific CD8+ cytotoxic T cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-alpha
Saudemont A, Corm S, Wickham T, Hetuin D, Quesnel B
Mol Ther . 2005 Jun; 11(6):950-9. PMID: 15922966
Acute myeloid leukemia (AML) cells can be differentiated into dendritic cells (DCs) using appropriate combinations of cytokines but generation of autologous antileukemic cytotoxic T cells using leukemic DCs remains difficult....
6.
NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells
Saudemont A, Jouy N, Hetuin D, Quesnel B
Blood . 2004 Nov; 105(6):2428-35. PMID: 15536145
Tumor dormancy is a phenomenon where small numbers of tumor cells persist in the host for months or years. We previously showed in the DA1-3b/C3H mouse model of acute myeloid...